Skip to content

A study comparing the efficacy and safety of peninsular counter-clockwise and super-pulsed matrix lasers in the treatment of atrophic acne scars

A study comparing the efficacy and safety of peninsular counter-clockwise and super-pulsed matrix lasers in the treatment of atrophic acne scars

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106573
Enrollment
Unknown
Registered
2025-07-25
Start date
2025-01-06
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne scarring

Interventions

A Group :Fractional carbon dioxide laser treatment method
B Group :Microneedle radiofrequency treatment method

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old, gender is not limited; 2. Meet the diagnostic criteria for atrophic acne scars, and the atrophic scars on the left and right faces are basically symmetrical; 3. Those who can persist in completing treatment and follow-up and do not use other methods for treatment during the period; 4. Subjects participate voluntarily and need to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; 2. Severe heart, liver, and kidney insufficiency, or those with autoimmune diseases; 3. Those who are equipped with a pacemaker or internal defibrillator; 4. Patients who have undergone laser, radiofrequency, chemical peeling, botulinum toxin injection, etc. within 3 months; 5. Use of photosensitizing drugs and tretinoin drugs within 1 month; 6. Taking glucocorticoids or other immunosuppressants and anticoagulants within 1 month; 7. History of grinding treatment and filler injection within 1 year; 8. History of infection, such as human immunodeficiency virus infection; 9. Those who cannot adhere to treatment; 10. Skin diseases such as broken, open wounds, purulent wounds, and active inflammatory herpes in the treatment area; 11. Those who suffer from coagulation dysfunction or other systemic diseases; 12. Those who have malignant tumors or skin tumors of unknown nature in the treatment area; 13. Subjects who are receiving chemotherapy/radiotherapy.

Design outcomes

Primary

MeasureTime frame
ECCA (échelle d'evaluation clinique des cicatrices d' acné);Self-assessment of patient satisfaction;Porphyrin;

Secondary

MeasureTime frame
Melanin index;Brown spot;Moisture content;Oil content;Erythema index;Ultraviolet spots;Texture;Wrinkle;Pore;

Countries

China

Contacts

Public ContactXu Yuanyuan

The First Hospital of China Medical University

xyy17101205@163.com+86 138 4016 5696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026